DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Israel ONLY.
Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous and homologous booster in adults aged 18 and older previously vaccinated with mRNA vaccines.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Israel at health.gov.il.